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proportion of infected patients, leads to cirrhosis and hepatocellu-
lar carcinoma. Severe extrahepatic manifestations are well recog-
nised, including mixed type 2 cryoglobulinemia, non-Hodgkins
lymphoma, porphyria cutanea tarda, and possibly type 2 diabetes.
In addition to the major extrahepatic syndromes associated with
chronic hepatitis C, several studies have pointed to a decrement
in health-related quality of life (HRQL) in hepatitis C, in compar-
ison to the general population [1–3]. HRQL is deﬁned as a person’s
subjective assessment of a range of conditions that can affect that
person’s perception of their state of health [3]. The most common
symptoms cited by patients with hepatitis C and that impact upon
their quality of life are fatigue, depression, anxiety, cognitive
impairment and painful muscle and joint symptoms. The biologi-
cal mechanisms and pathogenesis of these symptoms remain
uncertain. Some symptomsmay be due to the release of inﬂamma-
tory cytokines, or the direct presence of HCV in the central nervous
system. Those with greater histological hepatic inﬂammatory
activity may have worse fatigue, but symptoms tend to be present
irrespective of the degree of hepatic ﬁbrosis.
New DAA’s have resulted in striking SVR rates, even in
patients with advanced ﬁbrosis due to hepatitis C [4]. What then
are the effects of interferon-free treatments on HRQL? Younossi
and co-authors have examined quality of life in patients with
chronic hepatitis C in prospective trials of sofosbuvir and ledi-
pasvir, to assess alterations in HRQL before, during and after
treatment [5]. Their data provides an important opportunity to
assess patient-reported outcomes (PROMs) during treatment
and following an SVR, without the confounding effects of inter-
feron that markedly reduced ‘on-treatment’ quality of life indices
in previous studies [6–9].
The authors’ provide a detailed and comprehensive analysis
of HRQL and work productivity in patients with different stages
of hepatic ﬁbrosis treated with sofosbuvir and ledipasvir, orJournal of Hepatology 20
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Open access under CC BY-NC-ND license.sofosbuvir and ledipasvir plus ribavirin (RBV). Four question-
naires [Chronic Liver Disease Questionnaire-HCV (CLDQ-HCV),
Short Form-36 (SF-36) (encompassing eight domains),
Functional Assessment of Chronic Illness Therapy-Fatigue
(FACIT-F), Work Productivity and Activity Index: Speciﬁc Health
Problem (WPAI:SHP)] were administered to patients at baseline,
during, and after treatment with sofosbuvir and ledipasvir, with
or without ribavirin, in the ION-1, 2, and 3 clinical trials. Just over
1000 patients with available liver biopsies were included, and
42.1% of patients in the cohort were treated with a RBV-contain-
ing regimen for 8–24 weeks.
What are the major ﬁndings of the study? At baseline,
patients with more advanced ﬁbrosis had greater HRQL impair-
ments, predominantly related to physical functioning. However
HRQL domains related to emotional well-being and mental
health were similar regardless of the severity of ﬁbrosis.
Treatment-related anemia was observed more frequently in
patients with cirrhosis (48.0% in patients with cirrhosis vs.
32.4% in those with METAVIR stage F0-3). At week four of active
treatment, a decline in some HRQL scales was observed in
patients with mild ﬁbrosis. By the end of treatment, a more
substantial decline was observed in most HRQL domains.
However at the end of treatment, general health measured by
SF-36, emotional well-being by FACIT-F, and worry domain
by CLDQ-HCV signiﬁcantly improved in both ﬁbrosis cohorts.
By the SVR-12 follow-up visit most HRQL domains notably
improved from baseline in both ﬁbrosis cohorts, but work
productivity and health utility improved in patients with mild
ﬁbrosis only.
The on-treatment improvements rather than decrements in
HRQL observed in this study have not been previously reported.
Concomitant ribavirin administration in the regimen appeared
to be a factor in determining HRQL; in patients receiving sofosbu-
vir and ledipasvir moderate improvements in HRQL were
observed shortly after the start of treatment, but an opposite
effect was noted in patients receiving ribavirin. By multivariate
analysis, advanced ﬁbrosis was independently associated with
the degree of HRQL impairment and loss of work productivity,
but improvement of HRQL and work productivity after viral clear-
ance was not related to the stage of ﬁbrosis. Thus, the data sug-
gest that this interferon-free regimen is associated with15 vol. 63 j 300–302
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signiﬁcant ‘on-treatment’ improvement in most aspects of HRQL
for patients with early stage liver disease. Moreover, although
advanced hepatic ﬁbrosis is associated with HRQL impairment,
viral eradication with sofosbuvir and ledipasvir leads to HRQL
improvements irrespective of ﬁbrosis stage.
These improvements in PROMs are an encouraging accompa-
niment of an SVR. However, some decrements observed during
treatment with ribavirin-containing regimens will need to be
considered. The on-treatment impacts on HRQL are probably
attributable to the side effects of ribavirin, rather than the stage
of liver disease. In order to meet expectations, patients should
be informed that some decrement of HRQL might be observed
during treatment with DAA regimens, particularly those contain-
ing ribavirin.
HRQL studies are difﬁcult to conduct rigorously and may have
a risk of bias. Frequent weaknesses with HRQL studies include the
absence of appropriate placebo control groups, and consequent
problems with accounting for the effects of frequent clinical vis-
its, timing of clinical assessments, and other trial-related con-
founders. In many hepatitis C HRQL studies, there is frequently
insufﬁcient information on the mode of acquisition of hepatitis
C, the severity of liver disease, concomitant intravenous drug
and alcohol use, or prior treatment status. Nevertheless the cur-
rent study provides convincing and clinically signiﬁcant evidence
of a decrement in HRQL affecting both mental health and physical
health domains that can be improved by successful antiviral
treatment.
The study emphasizes some inherent difﬁculties. The cohort
includes a control group with ribavirin but did not contain a con-
trol group treated with interferon, thus making it difﬁcult to
gauge the size of the HRQL effect in the ribavirin recipients in this
study compared to interferon. The authors do make a comparison
to interferon-based HRQL data, but in a different population.
Ideally for HRQL studies the comparison and control groups
should be unaware of their diagnosis so that their perceptions
of health can be compared – clearly such a comparison is impos-
sible in therapeutic clinical trials for hepatitis C. However,
patients can be blinded to their own on-treatment results, to
avoid an inﬂuence on PROMs. No patients with decompensated
disease were included. Additionally, as noted above, there is no
mention of factors that may impact perception of HRQL, such
as the frequency of visits, and timing of clinical assessments.
The changes in HRQL scores are also small in magnitude despite
statistical signiﬁcance, and the ability of these instruments to
capture symptoms speciﬁc to hepatitis C in the population being
studied requires ongoing evaluation. A further question regarding
the inferences drawn from the data relates to improvements in
symptoms and PROMs following SVR in patients with advanced
ﬁbrosis. These improvements occurred during a period when
ﬁbrosis stage would have changed only marginally, suggesting
that the beneﬁt is derived from a reduction in viremia.
However, these changes were noted relatively early during treat-
ment and could reﬂect an accompanying reduction in ALT and
inﬂammatory change in the liver and perhaps other sites.
Current treatment of hepatitis C is largely aimed at preventing
progression of liver disease; these data suggest that successful
treatment will also alleviate symptoms. Successful treatment will
improve quality of life, in addition to reducing the stigma of hep-
atitis C and preventing the transmission and thus decreasing the
burden of chronic hepatitis C. Because of the costs of current
therapies, treatment is largely being directed to patients withJournal of Hepatology 201advanced ﬁbrosis to slow progression of their liver disease, to
improve liver function and prevent decompensation.
The results should be seen in context. The symptoms of
chronic hepatitis C add another dimension to the disease, since
the impaired physical and mental health, and social impact, of
chronic hepatitis C is considerable [10,11]. However, as a subjec-
tive perception, symptoms of hepatitis C are often regarded as
less important, and not given the same weight as discernible
advanced ﬁbrosis or end-stage liver disease. Nonetheless as ongo-
ing viral replication has an effect on these symptoms, the effect of
treatment and a SVR are important to ascertain. Moreover, health
economic outcomes are fundamentally inﬂuenced by HRQL data,
which are now considered critical secondary endpoints of clinical
trials of medical and surgical interventions for chronic diseases.
As shown in this study, symptoms are in fact associated with
the presence of the virus, and a treatment effect and effect of cure
on HRQL is evident. Will curing hepatitis C, and the symptomatic
improvements observed in these trials, translate into improved
work productivity and economic gain with these high cost regi-
mens? Presently payers seek improvements in ‘‘hard’’ measur-
able outcomes such as hospitalisation for hepatic
decompensation, transplantation rates, a reduction in hepatocel-
lular carcinoma, and deaths attributable to hepatitis C. Whether
these discernible improvements, in quality of life and productiv-
ity, will persuade payers to fund treatment for those with mini-
mal ﬁbrosis remains to be seen. The situation is akin to the
words of a famous rock band of the 1960s, ‘You can’t always get
what you want, but if you try sometimes, you just might get what
you need...’.Conﬂict of interest
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